申请人:FISONS plc
公开号:EP0164204A1
公开(公告)日:1985-12-11
There are described compounds of formula I,
in which one of the groups R and R3 has no significance and the other is hydrogen, phenyl or alkyl Cl to 6 optionally substituted by phenyl, and when R3 has no significance R can additionally represent alkanoyl Cl to 6,
one of the bonds --- is a double bond and the other is a single bond,
Ri, and at least one of R2, R4 and R5, may be the same or different and are selected from a pyridinyl, pyridimidinyl, thiazolyl, pyrazinyl, pyridazinyl, imidazolyl and phenyl ring, which rings may optionally be substituted by one or more of the groups halogen, -COOR5, -COR5, -CN, -CONH2, -S02NR5R6, -NR5R6, -OR5 or alkyl Cl to 6 which latter is optionally substituted by fluorine,
R5 and R6, which may be the same or different, each represent hydrogen or alkyl Cl to 6 optionally substituted by mono- or di-alkyl (Cl to 6) amino,
and the remainder of R2, R4 and R5 are selected from hydrogen, hydroxy, alkyl Cl to 6 and alkoxy Cl to 6 in addition to the significances given above,
or R1, and one of R4 and R5 have the significances given above and anadjacent pair of R2, R4 and R5 together form a -CH =CH-CH =CH- chain, or a pharmaceutically acceptable acid addition salt thereof.
Also described are processes for making certain of the compounds of formula I, formulations containing the compounds of formula I and their use as pharmaceuticals.
所述化合物为式 I、
其中基团 R 和 R3 中的一个无意义,另一个为氢、苯基或任选被苯基取代的 Cl 至 6 烷基,当 R3 无意义时,R 可另外代表 Cl 至 6 烷酰基、
其中一个键是双键,另一个键是单键、
Ri、R2、R4 和 R5 中的至少一个可以相同或不同,并选自吡啶基、吡啶亚氨 基、噻唑基、吡嗪基、哒嗪基、咪唑基和苯基环,这些环可任选被卤素、-COOR5、-COR5、-CN、-CONH2、-S02NR5R6、-NR5R6、-OR5 或 Cl 至 6 烷基中的一个或多个基团取代,后者可任选被氟取代、
R5 和 R6 可以相同或不同,各自代表氢或任选被单-或二-烷基(Cl 至 6)氨基取代的 Cl 至 6 烷基、
R2、R4 和 R5 的其余部分除上述含义外,还选自氢、羟基、Cl 至 6 的烷基和 Cl 至 6 的烷氧基、
或 R1、R4 和 R5 中的一个具有上述意义,且相邻的一对 R2、R4 和 R5 共同形成 -CH =CH-CH =CH- 链,或其药学上可接受的酸加成盐。
还描述了某些式 I 化合物的制造工艺、含有式 I 化合物的制剂及其作为药物的用途。